Trial Profile
Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs WASp gene therapy (Primary)
- Indications Wiskott-Aldrich syndrome
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 12 Jul 2023 Results published in the Blood
- 19 Jul 2022 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.